Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP623768.RA4ZuASsPzq4PSHsmAf4O2oCi4-rTMGWaaEbshDGyIs78130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP623768.RA4ZuASsPzq4PSHsmAf4O2oCi4-rTMGWaaEbshDGyIs78130_assertion type Assertion NP623768.RA4ZuASsPzq4PSHsmAf4O2oCi4-rTMGWaaEbshDGyIs78130_head.
- NP623768.RA4ZuASsPzq4PSHsmAf4O2oCi4-rTMGWaaEbshDGyIs78130_assertion description "[Selective inhibition of PI3K? (p110?) by GS-1101 has emerged as a promising therapy in chronic lymphocytic leukemia and indolent lymphomas.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP623768.RA4ZuASsPzq4PSHsmAf4O2oCi4-rTMGWaaEbshDGyIs78130_provenance.
- NP623768.RA4ZuASsPzq4PSHsmAf4O2oCi4-rTMGWaaEbshDGyIs78130_assertion evidence source_evidence_literature NP623768.RA4ZuASsPzq4PSHsmAf4O2oCi4-rTMGWaaEbshDGyIs78130_provenance.
- NP623768.RA4ZuASsPzq4PSHsmAf4O2oCi4-rTMGWaaEbshDGyIs78130_assertion SIO_000772 23676220 NP623768.RA4ZuASsPzq4PSHsmAf4O2oCi4-rTMGWaaEbshDGyIs78130_provenance.
- NP623768.RA4ZuASsPzq4PSHsmAf4O2oCi4-rTMGWaaEbshDGyIs78130_assertion wasDerivedFrom befree-20150227 NP623768.RA4ZuASsPzq4PSHsmAf4O2oCi4-rTMGWaaEbshDGyIs78130_provenance.
- NP623768.RA4ZuASsPzq4PSHsmAf4O2oCi4-rTMGWaaEbshDGyIs78130_assertion wasGeneratedBy ECO_0000203 NP623768.RA4ZuASsPzq4PSHsmAf4O2oCi4-rTMGWaaEbshDGyIs78130_provenance.